One Health Plaza<br>East Village Promenade
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.
With research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
Seqirus has a corporate office in Maidenhead, United Kingdom.
32 articles with Seqirus
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59 ® -adjuvanted, trivalent seasonal influenza vaccine (aTIV) in adults 65 years and older during the 2018/19 U.S. influenza season at the IDWeek 2020 virtual conference. 1 aTIV was found to be more effecti
Seqirus snagged approval for Fluad Quadrivalent, the first-and-only quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus announced that the U.S. Food and Drug Administration has approved AUDENZ™ Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A.1 AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic.
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus presented new scientific data at the Options for the Control of Influenza Conference in Singapore that demonstrated circulating influenza B/Victoria viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.
This decision makes the entire production process exclusively cell-based.
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs manufacturing facility in North Carolina.
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Seqirus today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older,1 extending the company's broad portfolio of influenza vaccine offerings. The approval also applies to the trivalent formulation of AFLURIA® (Influenza Vaccine).2
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
New studies highlight health and economic benefits of adjuvanted trivalent influenza vaccine amongst two at-risk populations - 65 years+ and young children
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
Seqirus today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compared with cell-derived vaccine viruses.
Seqirus today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina.
Seqirus has started to ship its portfolio of more than 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2018-2019 influenza season
GISAID announces a major contribution from Seqirus to support open and rapid sharing of influenza virus data
The Global Initiative on Sharing All Influenza Data (GISAID), a non-profit organization and public-private partnership dedicated to strengthening the world's defense against deadly influenza threats, today welcomed a €250,000 donation from Seqirus, a leading innovator in influenza vaccine technologies and pandemic response solutions.
APhA Celebrates Pharmacists' Contributions to Increasing U.S. Immunization Rates and Improving Health
The American Pharmacists Association (APhA) today announced the selection of recipients of its 2018 Immunization Champions Awards.
Seqirus Receives FDA Approval Of Afluria Quadrivalent (Influenza Vaccine) For People Five Years Of Age And Older In The U.S.